Entrada Therapeutics, Inc.: updates and filings

TRDANASDAQHealthcare · Pharmaceutical Preparations

Price

$5.32

November 17, 2026Market cap $203M

What Ploutos Investor adds for Entrada Therapeutics

Part of Ploutos Investor, €9.99 a month

See the plans
  • The full history: 3 fiscal years, from 2023
  • The estimated fair value, with its range and its certainty
  • The full analysis, 18 a month
  • More questions to the chat on its filings
  • Excel with every year
  • An email when it reports, changes its dividend or an officer buys

Sign in with a free account to see the last 5 fiscal years.

What comes next, and what happened

Its next results and latest dividend, and the filings that told of something: results, deals, people, debt. In plain words, each linked to the filing.

Next results

in 80 daysAround Feb 5, 2027 · for Q4 2026

last Nov 5, 2026next Feb 5, 2027

An estimate from when it has reported before, which has been regular. The company announces the date itself.

Its SEC filings

What it has filed lately, newest first, linked to the document itself.

Feb 26, 2026 latest annualNov 5, 2026 latest quarterly
  • Nov 5, 2026Quarterly reportfor the period to Sep 30, 2026
    Form10-Q
  • Nov 5, 2026Results of operations
    Form8-K
  • Oct 14, 2026Regulation FD disclosure, other material events
    Form8-K
  • Sep 10, 2026Over-5% holder statement (active) (amendment)
    FormSCHEDULE 13D/A
  • Aug 14, 2026Over-5% holder statement (passive) (amendment)
    FormSCHEDULE 13G/A
  • Aug 10, 2026Filing (amendment)
    Form144/A
  • Aug 5, 2026Quarterly reportfor the period to Jun 30, 2026
    Form10-Q
  • Aug 5, 2026Results of operations
    Form8-K
  • Jun 10, 2026Officer or director change, shareholder vote
    Form8-K
  • May 19, 2026Regulation FD disclosure
    Form8-K
  • May 7, 2026Quarterly reportfor the period to Mar 31, 2026
    Form10-Q
  • May 7, 2026Results of operations, Regulation FD disclosure
    Form8-K
  • Apr 29, 2026Additional annual meeting material
    FormDEFA14A
  • Apr 24, 2026Annual report to shareholdersfor the period to Dec 31, 2025
    FormARS
  • Apr 24, 2026Additional annual meeting material
    FormDEFA14A
  • Apr 24, 2026Annual meeting proxy statement
    FormDEF 14A
  • Feb 26, 2026Shares registered for employees
    FormS-8
  • Feb 26, 2026Annual reportfor the period to Dec 31, 2025
    Form10-K
  • Feb 26, 2026Results of operations
    Form8-K
  • Jan 8, 2026Results of operations, Regulation FD disclosure, other material events
    Form8-K
  • Dec 3, 2025Filing
    FormEFFECT
  • Dec 1, 2025Correspondence with the SEC
    FormCORRESP
  • Nov 25, 2025Over-5% holder statement (passive)
    FormSCHEDULE 13G
  • Nov 18, 2025Over-5% holder statement (active) (amendment)
    FormSCHEDULE 13D/A
  • Nov 14, 2025Over-5% holder statement (passive) (amendment)
    FormSCHEDULE 13G/A

From the company's record at the SEC (EDGAR). The topics of each 8-K are the item codes the company itself filed. Its whole record at the SEC, since Nov 10, 2016.

The full analysis

What do Entrada Therapeutics's filings show?

The filings are where every one of Entrada Therapeutics's figures comes from. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.

  • A fair value range built from the filings
  • Earnings quality, debt and red flags
  • Insider and institutional moves
  • The case for and the case against

All filings on EDGAR

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.